Dyno Therapeutics and Trisk Bio Form Strategic Manufacturing Partnership to Accelerate Gene Therapy Development
核心洞察
Dyno Therapeutics (搜索) and Trisk Bio (搜索) announced a strategic manufacturing partnership through Dyno's expanded Frontiers Program, creating an integrated developer-manufacturer network to reduce risk and accelerate gene therapy (搜索) development.
Trisk Bio (搜索) becomes the first Frontiers Manufacturing Partner, providing therapeutic developers with optimized production processes for Dyno's AI-designed AAV capsids (搜索) and greater certainty on manufacturing yields, costs, and timelines.
The expanded program aims to remove technical barriers that have historically slowed gene therapy (搜索) development and make it more viable to develop treatments for rare and ultra-rare diseases (搜索).
Dyno Therapeutics (搜索) and Trisk Bio (搜索) have announced a strategic manufacturing partnership through Dyno's expanded Frontiers Program, establishing an integrated developer-manufacturer network designed to reduce risk for gene therapy (搜索) developers and accelerate progress toward genetic agency. The partnership was announced during Dyno's Genetic Agency Technology Conference (GATC) in Boston.
First Manufacturing Partner in Expanded Program
Trisk Bio (搜索) becomes the first Frontiers Manufacturing Partner in Dyno's expanded Frontiers Program, which was originally announced in May 2025. The Dyno Frontiers Program was created to help innovative gene therapy (搜索) developers demonstrate the therapeutic potential of their genetic medicines by providing access to Dyno's AI-powered adeno-associated virus (搜索) (AAV) capsids and non-human primate (NHP) study expertise.
The newly expanded program extends access to a manufacturing marketplace for all Frontiers participants, with the goal of removing technical barriers that have historically slowed development efforts and limited patient impact.
Specialized Manufacturing Expertise
Trisk Bio (搜索) brings proven expertise in intensified, fully scalable, and high-purity AAV manufacturing to the partnership. As the first Dyno Frontiers Manufacturing Partner, Trisk has invested in establishing robust production processes specifically optimized for Dyno's leading gene delivery capsids, providing therapeutic developers with greater certainty on yield, cost, timelines, and overall manufacturing success.
"We've worked with Dyno for over a year, developing fully scalable manufacturing processes for several novel Dyno capsids, including purification exclusively by chromatography," said Gaurav Venkataraman, Chief Executive Officer of Trisk Bio (搜索). "We're impressed by Dyno's commitment to ensuring that their partners have a proven path to clinical and commercial scale."
Integrated Ecosystem Approach
The partnership represents the first initiative that integrates developers, technology providers, and AAV capsid manufacturers into an end-to-end partnership network. Eric Kelsic, Ph.D., CEO and Cofounder of Dyno Therapeutics (搜索), emphasized the significance of this integrated approach.
"As we grow the Dyno Frontiers Program, we're excited to build the first initiative that integrates developers, technology providers, and AAV capsid manufacturers, creating an end-to-end partnership network that promotes faster development of novel gene therapies at lower cost and with less execution risk for all of our partners," Kelsic stated.
Benefits for Therapeutic Developers
For therapeutic developers, the expanded Dyno Frontiers Program provides immediate access to manufacturers experienced with Dyno's capsids, reducing uncertainty, accelerating NHP study readiness, and establishing a path to clinical scale. The program aims to decrease information asymmetry, de-risk tech transfer, and accelerate progress to the clinic.
Boaz Levi, Co-founder and Chief Executive Officer of EpiCure Therapeutics (搜索), a gene therapy (搜索) company participating in Dyno's Frontiers Program, highlighted the value of the integrated approach. "When we were selecting a delivery platform for our epilepsy (搜索) program, we knew Dyno would be an ideal partner given their deep expertise in AI-enabled AAV capsid design and dedication to improving the entire process of gene delivery," Levi said. "They understood that reliable and scalable manufacturing support would also be valuable to developers like us who need to move quickly and confidently to bring much-needed therapies into the hands of patients."
Advancing Genetic Agency
The expanded Dyno Frontiers Program reinforces Dyno's commitment to advancing genetic agency: the capacity for patients to take action and improve their health at a genetic level through safe, effective, and widely accessible genetic treatments. Through this robust ecosystem, Dyno and Trisk aim to bring down the costs of gene therapy (搜索) development, making it more viable to develop new treatments for rare and ultra-rare diseases (搜索) that have historically been underexplored.
Kelsic noted that "expanding the Dyno Frontiers Program to now include manufacturing partners reflects our conviction that an ecosystem with healthy competition and collaboration is essential to broadening the patient impact of gene therapies and to enabling genetic agency, so that all patients can take action at the genetic level to live a healthier life."
Future Expansion Plans
Dyno is actively adding new Frontiers Manufacturing Partners to expand developer choice and manufacturing capacity, and is ready to partner with contract research organizations (CROs) as it continues to grow the Dyno Frontiers Program. Organizations interested in partnering can contact partnerwith@dynotx.com, while interested gene therapy (搜索) developers can learn more about accessing Dyno's capsid technology and manufacturing network at dynotx.com/frontiers-program.